Close Menu

NEW YORK – Predictive Oncology subsidiary Helomics has signed a pair of agreements to use its artificial intelligence-based platform in oncology decision making.

First, Helomics said today that it is partnering with the University of Pittsburgh Medical Center to use AI to potentially improve clinical decision making for ovarian cancer patients. In addition, Interpace Diagnostics said that it is working with Helomics to develop tools that diagnose and assess the risk of thyroid cancer.  

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.